سؤال

[fesall]

اول شى الله ايعينك يابومحمد على اسأتى شكلى قرقتك
بس هذى ضريبه المراقب :25:

الحين اذا لقيت شركه وبعرف تخصصها
مثل Avan
او
Cmgi

[ADVISER]

:) بسيطه طال عمرك ..ادخل على الـ

http://finance.yahoo.com (http://finance.yahoo.com)

ادخل رمز السهم

Cmgi

وبعديت اختار من القائمه على اليسار تحت كلمة


Company

ثم اضغط على

Profile (http://finance.yahoo.com/q/pr?s=CMGI)

[fesall]

ياسلام عليك

[fesall]

Gnbt هالشركه صارلها جم يوم بارتفاع
هل فى اخبار طيبه ولا من صناع السوق

[ADVISER]

هذا خبر كان بتاريخ 5/1/1006

الله يعينك على الترجمه :)

Generex Biotechnology Granted United States Patent in Connection With Its RapidMist(TM) Device

01/05/2006 09:00

TORONTO -- (MARKET WIRE) -- 01/05/06 -- Generex Biotechnology Corporation (NASDAQ: GNBT (http://portfolios.abcnews.go.com/quotes?tab=quote&tid=GNBT)), a leader in the area of buccal drug delivery, announced today that it has been granted another United States patent. The patent entitled, "Cleaning Compounds for and Method of Cleaning Valves and Actuators of Metered Dose Dispensers Containing Pharmaceutical Compositions," relates to the formulation and methodology for cleaning the Company's proprietary RapidMist device which is designed to deliver pharmaceutical products, including Oral-lyn(TM), the Company's proprietary oral insulin product, into the buccal cavity (the mouth) where it is absorbed into the bloodstream.

The patent covers a method of cleaning the RapidMist metered dose spray device, and a cleaning composition for such cleaning, to prevent the device from becoming clogged with medication. The cleaning composition is non-toxic and will not harm the user of the device following cleaning. This process makes the RapidMist device suitable for long-term, chronic use and ensures the accuracy and efficacy of the metered medication doses.

About Generex

Generex is engaged in the research and development of drug delivery systems and technologies. Generex has developed a proprietary platform technology for the delivery of drugs into the human body through the oral cavity (with no deposit in the lungs). The Company's proprietary liquid formulations allow drugs typically administered by injection to be absorbed into the body by the lining of the inner mouth using the Company's proprietary RapidMist(TM) device. The Company's flagship product, oral insulin (Oral-lyn(TM)), which has been approved for commercial sale in Ecuador for the treatment of patients with Type-1 and Type-2 diabetes, is in various stages of clinical trials around the world. Antigen Express is a wholly owned subsidiary of Generex. The core platform technologies of Antigen Express comprise immunotherapeutics for the treatment of malignant, infectious, allergic, and autoimmune diseases.

For more information, visit the Generex Web site at www.generex.com (http://www.generex.com).

Safe Harbor Statement: This release and oral statements made from time to time by Generex representatives concerning the same subject matter may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These statements can be identified by introductory words such as "expects," "plans," "intends," "believes," "will," "estimates," "forecasts," "projects" or words of similar meaning, and by the fact that they do not relate strictly to historical or current facts. Forward-looking statements frequently are used in discussing potential product applications, potential collaborations, product development activities, clinical studies, regulatory submissions and approvals, and similar operating matters. Many factors may cause actual results to differ from forward-looking statements, including inaccurate assumptions and a broad variety of risks and uncertainties, some of which are known and others of which are not. Known risks and uncertainties include those identified from time to time in the reports filed by Generex with the Securities and Exchange Commission, which should be considered together with any forward-looking statement. No forward-looking statement is a guarantee of future results or events, and one should avoid placing undue reliance on such statements. Generex cannot be sure when or if it will be permitted by regulatory agencies to undertake additional clinical trials or to commence any particular phase of clinical trials. Because of this, statements regarding the expected timing of clinical trials cannot be regarded as actual predictions of when Generex will obtain regulatory approval for any "phase" of clinical trials. Generex claims the protection of the safe harbor for forward-looking statements that is contained in the Private Securities Litigation Reform Act

[ADVISER]

هذا خبر نزل نزل اليوم

Generex Biotechnology Announces Commencement of a Long-Term Oral-lyn(TM) Clinical Study in Juvenile Patients With Type-1 Diabetes

01/09/2006 09:58

TORONTO -- (MARKET WIRE) -- 01/09/06 -- Generex Biotechnology Corporation (NASDAQ: GNBT (http://portfolios.abcnews.go.com/quotes?tab=quote&tid=GNBT)), a leader in the area of buccal drug delivery, announced today that it has commenced a long-term (six month) study of Oral-lyn, the Company's proprietary oral insulin spray product, in juvenile patients with Type-1 diabetes mellitus.

The Company previously reported the successful replacement, during a 12-day period, of short-acting subcutaneously injected pre-prandial insulin (breakfast, lunch, and dinner) (Humulin®) with Oral-lyn in 10 adult patients with Type-1 diabetes mellitus. The objective of this new study is to compare the use of Oral-lyn versus Humulin by juvenile patients at lunchtime during a 30-day period followed by a six-month replacement of Humulin with Oral-lyn at lunchtime. As in the previous study, this new study involves an Oral-lyn split-dose treatment, i.e. the application of Oral-lyn spray both before and after each meal. Generex believes that this approach offers a new diabetes treatment paradigm by offering improved efficacy (as Oral-lyn is better at mimicking the healthy body's natural insulin production) and patient compliance (no painful injections) resulting in greater metabolic stability thereby better controlling diabetes and reducing the complications associated with it. This study will demonstrate the application of that paradigm on a long-term basis in adolescent patients with Type-1 diabetes, a very challenging group to treat successfully.

This new study is taking place at the Institute of Endocrinology IEMYR in Quito, Ecuador and the principal investigator is Dr. Jaime Guevara-Aguirre. All of the participants in the study were referred to IEMYR for treatment by physicians in the South American medical community. The participants are: (a) 22 adolescents (11 males, 11 females) with a mean age of 14.4 years and a mean Body Mass Index (BMI) of 21.3, and (b) five young adults (two males, three females) with a mean age of 18.6 years and a mean BMI of 24.1. The mean age of the entire participant group is 15.2 years and the mean duration of the diabetes mellitus is 6.2 years.

Because the study participants were referred to IEMYR in varying states of metabolic control, it was appropriate to stabilize them using standardized methodologies prior to the commencement of the study. Upon referral to IEMYR, each participant received a schedule of baseline insulin glargine twice-a-day (BID) (2/3 in the morning, 1/3 in the evening) in addition to three-times-a-day (TID) pre-prandial short-acting insulin. Metabolic stability was achieved by making small gradual subject-specific adjustments to the insulin schedule every four days and implementing dietary adjustments. Glucose was monitored frequently (six-point glucose daily profile for 20 days). Fructosamine and glycosylated hemoglobic (HbA1c) were obtained at the commencement of the stabilization program and after 20 days.

The 27 subjects were metabolically stabilized in a very short period of time (20 days) as documented by important and statistically significant improvements in the six-point daily glucose profiles, protein glycosylation parameters, Fructosamine, and HbA1c that displayed strong correlation:

[المحلل المجتهد]

هذا خبر كان بتاريخ 5/1/1006

الله يعينك على الترجمه :)

Generex Biotechnology Granted United States Patent in Connection With Its RapidMist(TM) Device

01/05/2006 09:00

TORONTO -- (MARKET WIRE) -- 01/05/06 -- Generex Biotechnology Corporation (NASDAQ: GNBT (http://portfolios.abcnews.go.com/quotes?tab=quote&tid=GNBT)), a leader in the area of buccal drug delivery, announced today that it has been granted another United States patent. The patent entitled, "Cleaning Compounds for and Method of Cleaning Valves and Actuators of Metered Dose Dispensers Containing Pharmaceutical Compositions," relates to the formulation and methodology for cleaning the Company's proprietary RapidMist device which is designed to deliver pharmaceutical products, including Oral-lyn(TM), the Company's proprietary oral insulin product, into the buccal cavity (the mouth) where it is absorbed into the bloodstream.

The patent covers a method of cleaning the RapidMist metered dose spray device, and a cleaning composition for such cleaning, to prevent the device from becoming clogged with medication. The cleaning composition is non-toxic and will not harm the user of the device following cleaning. This process makes the RapidMist device suitable for long-term, chronic use and ensures the accuracy and efficacy of the metered medication doses.

About Generex

Generex is engaged in the research and development of drug delivery systems and technologies. Generex has developed a proprietary platform technology for the delivery of drugs into the human body through the oral cavity (with no deposit in the lungs). The Company's proprietary liquid formulations allow drugs typically administered by injection to be absorbed into the body by the lining of the inner mouth using the Company's proprietary RapidMist(TM) device. The Company's flagship product, oral insulin (Oral-lyn(TM)), which has been approved for commercial sale in Ecuador for the treatment of patients with Type-1 and Type-2 diabetes, is in various stages of clinical trials around the world. Antigen Express is a wholly owned subsidiary of Generex. The core platform technologies of Antigen Express comprise immunotherapeutics for the treatment of malignant, infectious, allergic, and autoimmune diseases.

For more information, visit the Generex Web site at www.generex.com (http://www.generex.com).

Safe Harbor Statement: This release and oral statements made from time to time by Generex representatives concerning the same subject matter may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These statements can be identified by introductory words such as "expects," "plans," "intends," "believes," "will," "estimates," "forecasts," "projects" or words of similar meaning, and by the fact that they do not relate strictly to historical or current facts. Forward-looking statements frequently are used in discussing potential product applications, potential collaborations, product development activities, clinical studies, regulatory submissions and approvals, and similar operating matters. Many factors may cause actual results to differ from forward-looking statements, including inaccurate assumptions and a broad variety of risks and uncertainties, some of which are known and others of which are not. Known risks and uncertainties include those identified from time to time in the reports filed by Generex with the Securities and Exchange Commission, which should be considered together with any forward-looking statement. No forward-looking statement is a guarantee of future results or events, and one should avoid placing undue reliance on such statements. Generex cannot be sure when or if it will be permitted by regulatory agencies to undertake additional clinical trials or to commence any particular phase of clinical trials. Because of this, statements regarding the expected timing of clinical trials cannot be regarded as actual predictions of when Generex will obtain regulatory approval for any "phase" of clinical trials. Generex claims the protection of the safe harbor for forward-looking statements that is contained in the Private Securities Litigation Reform Act





مَنحتْ تقنية Generex الحيويةُ براءة إختراع أمريكية بالإرتباط مع RapidMistها (ع ت) أداة
01 / 05 / 2006 09:00
تورنتو -- (سلك سوقِ) -- 01/05/06 -- شركة تقنية Generex الحيويةِ (ناسداك: جي إن بي تي) , a زعيم في منطقةِ توزيعِ عقاقير buccal، أعلنَ اليوم بأنّه مُنِحَ براءةَ إختراع أمريكيةَ أخرى. براءة الإختراع أَهّلتْ، "تنظيف مركّباتِ لوطريقةِ لتنظيف الصماماتِ ومشغّلاتِ صيادلة الجرعةِ المُقاسِ الذين يَحتوونَ تراكيبَ صيدليةَ، "يَتعلّقُ بالصياغةِ وعِلْمِ المنهج لتنظيف ملكيةِ أداةِ شركةَ RapidMist الذي يُصمّمانِ لتَسليم المُنتَجاتِ الصيدليةِ، بضمن ذلك lyn الشفهي (ع ت)، مُنتَج أنسيولينِ الشركةَ الإمتلاكيَ الشفهيَ، إلى تجويفِ buccal (الفَمّ) حيث أنَّ ه إمتصَّ إلى مجرىِ الدمّ.
الأغطية المسجّلة a طريقة تنظيف RapidMist قاستْ أداةَ رذاذِ جرعةِ، وa تنظيف تركيبِ لهذا تنظيف، لمَنْع الأداة من أَنْ يُصبحَ مُعَرقَل بالدواءِ. إنّ تركيبَ التنظيف غيرُ سامُّ وسوف لَنْ يَآْذي مستعملَ الأداةِ بعد التنظيف. تَجْعلُ هذه العمليةِ أداةَ RapidMist مناسبة للإستعمالِ المُزمنِ الطويل المدى وتَضْمنُ الدقةَ وكفاءةَ جُرَعِ الدواءِ المُقاسةِ.
حول Generex
Generex مَشْغُولُ في بحث وتطويرِ أنظمة توزيع العقاقيرِ والتقنياتِ. Generex طوّرَ a تقنية رصيفِ إمتلاكيةِ لتسليمِ المخدّراتِ إلى الجسمِ الإنسانيِ خلال التجويفِ الشفهيِ (بدون إيداعِ في الرئتينِ). تَسْمحُ صياغاتُ الشركةَ الإمتلاكية السائلة للمخدّراتِ أدارتْ نموذجياً بالحقنِ الّتي سَتُمتَصُّ إلى الجسمِ ببطانةِ الفَمِّ الداخليِ تَستعملُ ملكيةَ الشركةَ RapidMist (ع ت) أداة. منتج الشركةَ الرئيسي، أنسيولين شفهي (lyn شفهي (ع ت))، الذي صُدّقَ للبيعِ التجاريِ في إكوادور لمعالجةِ المرضى بالنوعِ -1 ونوع -2 مرض السكّر، في المراحلِ المُخْتَلِفةِ مِنْ التجارب الطبيَّةِ حول العالمِ. سريع مُسْتَضدِ a إمتلكَ شركة تابعةَ كليةً Generex. تَشْملُ تقنياتُ الرصيفِ الرئيسيةِ لسريعِ المُسْتَضدِ immunotherapeutics لمعالجةِ الأمراضِ الذاتية المناعةِ والحسّاسةِ والمعديةِ والخبيثةِ.
للمزيد من المعلومات، يَزُورُ موقعَ ويب Generex في www.generex.com (http://www.generex.com)..
بيان الميناءِ الآمنِ: هذا الإطلاقِ والبياناتِ الشفهيةِ جَعلا من وَقتٍ لآخَرَ مِن قِبل ممثلي Generex يَتعلّقانِ بنفس مادةِ البحث قَدْ تَحتوي "بيانات تقدمية" ضمن معنى فعلِ إصلاحِ مقاضاةِ السندات المالية الخاصِّ مِنْ 1995. هذه البياناتِ يُمْكِنُ أَنْ تُميّزَ بالكلماتِ التمهيديةِ مثل "تَتوقّعُ، "" خطط، "" يَنْوى، "" إعتقادات، "" سَ، "" يُخمّنُ، "" توقّعات، ""مشاريع" أَو كلمات المعنى المماثلِ، ومِن قِبل الحقيقة بإِنَّهُمْ لا يَتعلّقونَ ببصرامة إلى الحقائقِ التأريخيةِ أَو الحاليةِ. البيانات التقدمية كثيراً مستعملة في مُنَاقَشَة تطبيقاتِ المُنتَجِ المحتملةِ، تعاون محتمل، نشاطات تطويرِ مُنتَجِ، دِراسات سريرية، مقالات وموافقات تنظيمية، وأمور تشغيل مماثلةِ. العديد مِنْ العواملِ قَدْ تُسبّبُ نَتائِجَ فعليةَ للإختِلاف عن بياناتِ تقدميةِ، بضمن ذلك الفرضياتِ الخاطئةِ وa تَشْكِيلة واسعة مِنْ الأخطارِ والحيرةِ، البعض مِنْ الذي يَعْرفُ والآخرونُ الذي منه لَيسوا. الأخطار والحيرة المعروفة يَتضمّنانِ تلك المُمَيَّزةِ من وَقتٍ لآخَرَ في التقاريرِ حَفظتْ مِن قِبل Generex بلجنة الأوراق المالية والتبادلِ، التي يجب أنْ تؤخذ بنظر الإعتبار سوية بأيّ بيان تقدمي. لا بيانَ تقدميَ a ضمان النَتائِجِ أَو الأحداثِ المستقبليةِ، وواحد يَجِبُ أَنْ يَتجنّبَ وَضْع الإعتمادِ لا داعي لهِ على مثل هذه البياناتِ. Generex لا يُمكنُ أَنْ يَكُونَ متأكّدَ عندما أَو إذا هو سَيَكُونُ مسموح بالوكالاتِ التنظيميةِ أَنْ يَفترضَ تجارب طبيَّةَ إضافيةَ أَو لشَرْع أيّ مرحلة معيّنة مِنْ التجارب الطبيَّةِ. بسبب هذا، بيانات بخصوص التوقيت المتوقّع للتجارب الطبيَّةِ لا يُمْكن أنْ يُعتَبرَ تنبؤاتَ فعليةَ عندما Generex سَتَحْصلُ على الموافقةِ التنظيميةِ لأيّ "مرحلة" التجارب الطبيَّةِ. يَدّعي Generex حماية الميناءِ الآمنِ للبياناتِ التقدميةِ التي مُحتَويةُ في فعلِ إصلاحِ مقاضاةِ السندات المالية الخاصِّ


:25: مترجم يبحث عن عمل :25:

[المحلل المجتهد]

هذا خبر نزل نزل اليوم

Generex Biotechnology Announces Commencement of a Long-Term Oral-lyn(TM) Clinical Study in Juvenile Patients With Type-1 Diabetes

01/09/2006 09:58

TORONTO -- (MARKET WIRE) -- 01/09/06 -- Generex Biotechnology Corporation (NASDAQ: GNBT (http://portfolios.abcnews.go.com/quotes?tab=quote&tid=GNBT)), a leader in the area of buccal drug delivery, announced today that it has commenced a long-term (six month) study of Oral-lyn, the Company's proprietary oral insulin spray product, in juvenile patients with Type-1 diabetes mellitus.

The Company previously reported the successful replacement, during a 12-day period, of short-acting subcutaneously injected pre-prandial insulin (breakfast, lunch, and dinner) (Humulin®) with Oral-lyn in 10 adult patients with Type-1 diabetes mellitus. The objective of this new study is to compare the use of Oral-lyn versus Humulin by juvenile patients at lunchtime during a 30-day period followed by a six-month replacement of Humulin with Oral-lyn at lunchtime. As in the previous study, this new study involves an Oral-lyn split-dose treatment, i.e. the application of Oral-lyn spray both before and after each meal. Generex believes that this approach offers a new diabetes treatment paradigm by offering improved efficacy (as Oral-lyn is better at mimicking the healthy body's natural insulin production) and patient compliance (no painful injections) resulting in greater metabolic stability thereby better controlling diabetes and reducing the complications associated with it. This study will demonstrate the application of that paradigm on a long-term basis in adolescent patients with Type-1 diabetes, a very challenging group to treat successfully.

This new study is taking place at the Institute of Endocrinology IEMYR in Quito, Ecuador and the principal investigator is Dr. Jaime Guevara-Aguirre. All of the participants in the study were referred to IEMYR for treatment by physicians in the South American medical community. The participants are: (a) 22 adolescents (11 males, 11 females) with a mean age of 14.4 years and a mean Body Mass Index (BMI) of 21.3, and (b) five young adults (two males, three females) with a mean age of 18.6 years and a mean BMI of 24.1. The mean age of the entire participant group is 15.2 years and the mean duration of the diabetes mellitus is 6.2 years.

Because the study participants were referred to IEMYR in varying states of metabolic control, it was appropriate to stabilize them using standardized methodologies prior to the commencement of the study. Upon referral to IEMYR, each participant received a schedule of baseline insulin glargine twice-a-day (BID) (2/3 in the morning, 1/3 in the evening) in addition to three-times-a-day (TID) pre-prandial short-acting insulin. Metabolic stability was achieved by making small gradual subject-specific adjustments to the insulin schedule every four days and implementing dietary adjustments. Glucose was monitored frequently (six-point glucose daily profile for 20 days). Fructosamine and glycosylated hemoglobic (HbA1c) were obtained at the commencement of the stabilization program and after 20 days.

The 27 subjects were metabolically stabilized in a very short period of time (20 days) as documented by important and statistically significant improvements in the six-point daily glucose profiles, protein glycosylation parameters, Fructosamine, and HbA1c that displayed strong correlation:


تُعلنُ تقنية Generex الحيويةُ بدء a lyn شفهي طويل المدى (ع ت) دراسة سريرية في المرضى الأحداثِ بالنوعِ -1 مرض السكّر
01 / 09 / 2006 09:58
تورنتو -- (سلك سوقِ) -- 01/09/06 -- شركة تقنية Generex الحيويةِ (ناسداك: جي إن بي تي) , a زعيم في منطقةِ توزيعِ عقاقير buccal، أعلنَ اليوم بأنّ شَرعَ a مدى بعيد (ستّة شهرِ) دراسة lyn شفهية، مُنتَج رذاذِ أنسيولينِ الشركةَ الإمتلاكيَ الشفهيَ، في المرضى الأحداثِ بالنوعِ -1 داء السكّري.
أبلغتْ الشركةُ عن البديلِ الناجحِ سابقاً، أثناء a فترة 12 أيام، مِنْ التمثيل القصيرِ حَقنَ أنسيولينَ قبل الطّعامَ تحت الجلد (فطور، غداء، وعشاء) (Humulin®) مَع lyn شفهي في 10 مرضى بالغينِ بالنوعِ -1 داء السكّري. إنّ هدفَ هذه الدراسةِ الجديدةِ أَنْ تُقارنَ إستعمالَ lyn شفهي مقابل Humulin مِن قِبل المرضى الأحداثِ في وقتِ الغداء أثناء a فترة 30 أيام تَلتْ مِن قِبل a بديل ستّة شهور لHumulin مَع lyn شفهي في وقتِ الغداء. كما في الدراسةِ السابقةِ، تَتضمّنُ هذه الدراسةِ الجديدةِ إنشقاقِ lyn شفهي يَداوي معالجةً، وبمعنى آخر: . تطبيق رذاذِ lyn الشفهي كلتا قَبلَ وَبَعد كُلّ وجبة طعام. يَعتقدُ Generex بِأَنَّ هذه النظرةِ تَعْرضُ a مثال معالجةِ مرض السكّرِ جديدِ بعرض الكفاءةِ المُحسَّنةِ (كlyn شفهي أفضلُ في mimicking، إنتاج أنسيولينِ الجسمِ الصحّيِ الطبيعيِ) وإلتزام صبور (لا حُقَنَ مؤلمةَ) يُؤدّي إلى الإستقرارِ الأيضيِ الأعظمِ بذلك مراهن يُسيطرُ على مرض السكّرِ ويُخفّضَ التعقيداتَ إرتبطَ به. هذه الدراسةِ سَتَعْرضُ تطبيقَ ذلك المثالِ على a قاعدة طويلة المدى في المرضى المراهقينِ بالنوعِ -1 مرض السكّر , a مجموعة صعبة جداً للمُعَالَجَة بنجاح.
هذه الدراسةِ الجديدةِ تَحْدثُ في معهدِ طبّ غُدَد صمّاءِ آي إي إم واي آر في كويتو، إكوادور والمحقّق الرئيسي الدّكتورُ جيم غيفارا أجوير. كُلّ المشاركين في الدراسةِ أُشيرتْ إلى آي إي إم واي آر للمعالجةِ مِن قِبل الأطباءِ في المجموعة الطبيةِ الأمريكية الجنوبيةِ. إنّ المشاركين: (a) 22 مُراهق (11 ذكر، 11 أنثى) مَع a يَعْنونَ عُمرَ مِنْ 14.4 سنةِ وa دليل كتلةِ جسم متوسطِ (بي إم آي) 21.3، و(b) خمسة شبابِ (ذكران، ثلاث إناث) مَع a يَعْنونَ عُمرَ مِنْ 18.6 سنةِ وa دليل كتلةِ جسم متوسطِ مِنْ 24.1. إنّ العُمرَ المتوسطَ كامل مجموعةِ المشاركِ 15.2 سنةُ والمدّةُ المتوسطةُ لداء السكّري 6.2 سنةُ.
لأن مشاركي الدراسةَ أُشيروا إلى آي إي إم واي آر في تَفَاوُت ولاياتِ السيطرةِ الأيضيةِ، هو كَانَ ملائمَ لتَثبيتهم يَستعملونَ منهجياتَ قياسيةَ قبل بدءِ الدراسةِ. على الإحالةِ إلى آي إي إم واي آر، كُلّ مشارك إستلمَ a جدول أنسيولينِ خطّ أساسِ glargine مرّتين في اليوم (عَرضَ) (2/3 في الصباحِ، 1/3 في المساء) بالأضافة إلى أوقاتَ ثلاثة في اليوم (تي آي دي) أنسيولين قصير بالوكالة قبل الطّعام. الإستقرار الأيضي أُنجزَ بجَعْل تعديلاتِ الموضوعِ الصغيرِ المعيّنةِ التدريجيِ إلى جدولِ الأنسيولينَ كُلّ أربعة أيامِ ويُطبّقُ تعديلاتَ غذائيةَ. الجلوكوز روقبَ كثيراً (يَكْتبُ جلوكوزُ نقطةِ ستّة لمحة عن يومياً ل20 يومِ). Fructosamine وglycosylated hemoglobic (HbA 1 c) حُصِلا عليه في بدءِ برنامجِ الإستقرارَ وبعد 20 يومِ.
المواضيع الـ27 ثُبّتتْ بشكل أيضي في وقت قصير جداً (20 يوم) كما هي موثّقة من قبل التحسينات المهمة والهامّة بشكل إحصائي في لمحاتِ حياة جلوكوزِ النقطةَ ستّة اليوميةَ، بروتين glycosylation بارامترات، Fructosamine، وHbA 1 c ذلك الإرتباطِ القويِ المَعْرُوضِ:



لازلت ابحث عن عمل هل من وظيفة :25:

[fesall]

مشكورين
شباب مافى موقع ترجمه او برنامج انزله ايترجم المواقع :rolleyes:

[المحلل المجتهد]

مشكورين
شباب مافى موقع ترجمه او برنامج انزله ايترجم المواقع :rolleyes:


تآمر امر :25:


إضغط هنا (http://www.shajjar.net/site/modules.php?name=Downloads&d_op=getit&lid=56)